Stock analysis, AI verdict, fundamentals & technical signals
Rating: BUY
Price: $2.59 Analyst target: $11.00 Upside: 324.71%
Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in Israel, Brazil, the rest of Latin America and internationally. The company is headquartered in Karmiel, Israel.
See the full interactive analysis & chart →Informational only — not investment advice.